

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**廣東康華醫療集團股份有限公司**  
**GUANGDONG KANGHUA HEALTHCARE GROUP CO., LTD.\***  
*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 3689)**

**RESIGNATION AND APPOINTMENT OF DIRECTOR**

The Board hereby announces that:

- (i) Mr. Lv Yubo has tendered his resignation as a non-executive Director; and
- (ii) Mr. Jiang Xiwen has been appointed as a non-executive Director.

The above changes will take effect from 17 October 2025.

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of Guangdong Kanghua Healthcare Group Co., Ltd.\* (廣東康華醫療集團股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes in composition of the Board.

**1. RESIGNATION OF DIRECTOR**

Mr. Lv Yubo (“**Mr. Lv**”) has tendered his resignation as a non-executive Director to devote more time to his other endeavours, with effect from 17 October 2025. Mr. Lv has confirmed that he has no disagreement with the Board and he is not aware of any matter in relation to his resignation as a non-executive Director that should be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”). The Board would like to take this opportunity to express its sincere gratitude to Mr. Lv for his valuable contribution to the Company during his tenure of service.

## 2. APPOINTMENT OF DIRECTOR

The Board has convened a meeting on 17 October 2025, in accordance with the requirements of the Company Law of the People’s Republic of China and articles of associations of the Company. The Board is pleased to announce that in view of Mr. Lv’s resignation, Mr. Jiang Xiwen (“**Mr. Jiang**”) has been appointed as a non-executive Director for an initial term commencing from 17 October 2025 (“**Effective Date**”) until the conclusion of the next annual general meeting of the Company and shall be eligible for re-election.

The biographical details of Mr. Jiang are set out below.

Mr. Jiang Xiwen (蔣析文), aged 43, has been a talent introduced under the “Strong Pharmaceutical Scholars Program\*” (強藥學者計劃) at Guangdong Pharmaceutical University\* (廣東藥科大學) since June 2025, currently serves as a research fellow at the School of Basic Medical Sciences\* (基礎醫學院) of Guangdong Pharmaceutical University\* (廣東藥科大學, Kanghua Hospital also serves as a teaching hospital affiliated with this university). Mr. Jiang has also held leadership positions in several professional associations, including being the deputy chairman of the Medical Device Professional Committee of the Guangdong Food and Drug Evaluation and Certification Technology Association\* (廣東省食品藥品審評認證技術協會醫療器械專委會), and the deputy chairman of the Guangdong Medical Device Management Society\* (廣東省醫療器械管理學會). Mr. Jiang holds a Doctor of Philosophy in Microbiology from The University of Hong Kong, a Master of Science in Clinical Laboratory Medicine from The Hong Kong Polytechnic University, a Master of Science in Microbiology from the Wuhan Institute of Virology, Chinese Academy of Sciences\* (中科院武漢病毒研究所), and a Bachelor of Science in Biotechnology from Huazhong University of Science and Technology\* (華中科技大學).

Before his appointment became effective, on 17 October 2025, Mr. Jiang had obtained the legal advice from a firm of solicitors qualified to advise on Hong Kong law referred to in Rule 3.09D of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “**Listing Rules**”) and had confirmed that he understood his obligations as a non-executive Director, the requirements under the Listing Rules that are applicable to him as a non-executive Director and the possible consequences of making a false declaration or giving false information to the Hong Kong Stock Exchange.

Under the service contract with the Company, Mr. Jiang will be entitled to a fixed director’s fees of RMB120,000 per annum, which is determined by the Board and the remuneration committee of the Company with reference to the market rates for such position, and his qualifications, experience and responsibilities with the Company.

Save as disclosed above, as at the date of this announcement, Mr. Jiang (i) does not hold any other positions with the Group, nor did he hold any directorship in any public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any other major appointment or professional qualification; (iii) does not have any interest or is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) does not have any relationship with any Directors, supervisors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company or its subsidiaries. Save as disclosed above, as far as the Board is aware, there is no other matter in relation to the appointment of Mr. Jiang that needs to be brought to the attention of the Shareholders or the Hong Kong Stock Exchange, nor any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

### 3. ACKNOWLEDGEMENT

The Board would like to express its sincere gratitude to Mr. Lv for his invaluable contribution to the Group during his term of service as a non-executive Director. The Board would also like to extend its warmest welcome to Mr. Jiang on his new appointment to the Board.

By order of the Board  
**Guangdong Kanghua Healthcare Group Co., Ltd.\***  
**WANG Junyang**  
*Chairman and Executive Director*

Hong Kong  
17 October 2025

*As at the date of this announcement, the Board comprises:*

*Executive Directors:*

Mr. Wang Junyang (*Chairman*)  
Mr. Chen Wangzhi (*Chief executive officer*)  
Mr. Wong Wai Hung (*Vice chairman*)  
Ms. Wang Aiqin

*Independent non-executive Directors:*

Dr. Chen Keji  
Ms. Lam Shiu Ling Cecilia  
Mr. Chan Sing Nun

*Non-executive Director:*

Mr. Jiang Xiwen

\* *For identification purposes only*